P rimary aldosteronism is the most common form of secondary hypertension comprising >11% of the patients referred to specialized centers for hypertension. 1 The term primary denotes our ignorance of the underlying cause(s)/ mechanism(s) 2 due largely to the lack of ideal models for in vitro and ex vivo investigation of the regulation of aldosterone production. In fact, we still rely on the H295R line and its derived clone HAC15; as adrenocortical carcinoma cells, they may not closely recapitulate the physiological and pathophysiological regulations of aldosterone secretion. Until recently, the lack of biomarkers specific for aldosterone-producing adenoma (APA) cells for identification and isolation and, thereby, ex vivo investigation, has been a major hurdle in this field. We, herein, review available knowledge on zona glomerulosa (ZG) and aldosterone-producing cell markers with the aim of providing updated information on the state-of-the art on this topic. The Table summarizes the information that could be gathered for each candidate marker on its specificity, intracellular localization, usefulness, and drawbacks for isolating aldosteroneproducing cells from the ZG and APAs. For the sake of clarity, the text below follows the order of markers shown in this Table. For further roles and functions of the markers, see data in the online-only Data Supplement and figures.
Aldosterone Synthase as a Biomarker of the Aldosterone-Producing Cells
The adrenocortical ZG is characterized by cells lying directly beneath the capsule and arranged in clusters or arches (glomus in Latin means ball) and is the main site of aldosterone synthesis. Rodent ZG comprises 4 to 6 layers of cells in a continuous band occupying 2% to 15% of the gland volume depending on salt intake. In humans, its size varies with age: in infants and young adults, the ZG resembles the rodent adrenal with a relatively homogeneous layer of ZG cells, while after the fourth decade, it seems as a discontinuous layer comprising no >5% of the total adrenocortical volume. 3 The recent development of specific antibodies against human 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) now allows an accurate localization of the cells producing cortisol and aldosterone in the normal adrenal cortex and APA. 3 These antibodies show that some human APAs contain not only CYP11B2-expressing cells but also CYP11B1-positive cells. [4] [5] [6] [7] In some APAs, CYP11B2 or CYP11B1 are expressed in different cells; in others cells express both CYP11B1 and CYP11B2. [4] [5] [6] [7] These findings challenge the classic view of APA as a single, well-demarcated nodule comprising only cells producing excess aldosterone. 4 Clusters of CYP11B2-positive cells, called aldosterone-producing cell clusters, have been identified in the subcapsular area of adrenals with and without an APA, 8 including some without high blood pressure. 9 This suggests no clear boundary between the APA and adjacent ZG tissue and that subcapsular micronodules might be the initial foci for the development of APA, a contention that remains to be proven. 4 Our initial observation that compared with the normal adrenal tissues, CYP11B2 gene expression was not increased in some APAs fulfilling the 4 corners' criteria, 10 confirmed by Boulkroun et al, 11 along with the aforementioned identification of CYP11B1-positive cells within the APA, challenged the hypothesis of CYP11B2 as a unique marker of APA. 4, 6, 7, 12 Thus, APA made entirely of cells expressing abnormally high levels of CYP11B2 are at one end of the spectrum, and APA with CYP11B2 expression similar to the normal ZG cells at the opposite end. In patients with adrenal vein samplingproven unilateral production of aldosterone, but an adenoma that does not clearly express CYP11B2, hyperaldosteronism may be sustained by unilateral expansion of aldosterone-producing cell number and by concomitant cortical aldosteroneproducing cell clusters. 16 thus making this channel a candidate marker of APAs. However, its downregulation in APA precludes use of TASK-2 as a tool for APA cell isolation: its possible use is as a negative selector (eg, to remove non-APA cells from a specimen).
Several mutations in other genes regulating ion homeostasis and cell membrane potential have been found in sporadic APAs and familial forms of primary aldosteronism (reviewed in 17 ). These mutations do not involve all APAs; for example, the most common are the Kir3.4 channel (KCNJ5) mutations that occur in 30% to 70% of the APA with wide geographic variations [18] [19] [20] [21] ; ion channel mutations, therefore, cannot be regarded as universal markers of these tumors. At variance with an early suggestion, HAC15 human adrenal cortical cells with mutations involving the Kir3.4 channels do not increase proliferation, but rather the opposite. 22, 23 Finally, different mutations can be harbored within the same APA. 21, 24 Thus, the somatic mutations of K channels cannot be regarded as markers of APA because, by definition, a marker should be a trait of the disease. However, recent data suggest that some Kir3.4 mutations could show sensitivity to certain drugs, which may thus be an indication of the presence of mutated APA.
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CD56: The Intercellular Glue
We found CD56 immunostaining of the neural cell adhesion molecule, known as CD56 (NM_000615), which fades moving toward the zona fasciculata (ZF), is strong in the ZG and APAs. We thus suggested that CD56 may be a marker of ZG and APA (see data in the online-only Data Supplement). 26 We also showed that CD56, located on the cell surface, can be used to isolate aldosterone-producing cells from ZG and APAs on immunobinding, 26 thus distinguishing CD56-positive and CD56-negative cells. Of note, on electron microscopy the CD56-positive cells were densely filled with mitochondria, thus displaying the features of ZG aldosterone-producing cells. Moreover, CYP11B2 gene expression levels and aldosterone concentrations in the culture media are markedly higher in the former than in the latter, evidence that CD56 is a marker of ZG and aldosterone-producing cells. 27 Thus, CD56 is a membrane marker of ZG and APA cells and a useful tool to isolate these cells, with the caveats that it is not expressed in all ZG cells and is highly expressed also in the adrenal medulla. 
Dab2: The Driver of Directional Motor in the Cell
Dab2 (NM_001343) is a 96 kD phosphoprotein isolated from murine macrophages involved in colony stimulating factor-1 signaling and mitogenic pathways (see data in the onlineonly Data Supplement). 28 In the rat, it is expressed in the adrenal ZG but not the ZF-ZR (zona reticularis) or medulla. 29 In H295R cells, Dab2 overexpression yielded 2 alternatively spliced Dab2 isoforms (of 100 KDa and 75), which enhanced angiotensin II-stimulated aldosterone secretion. 29 Low-salt diet treatment doubled Dab2 immunoreactivity of the 100 KDa Dab2 isoform, along with enhanced ZG proliferation, suggesting that the longer isoform acts as a sensor of [Na + ] changes. 29 In the adrenal cortex, Dab2 colocalizes with CYP11B2, 29, 30 whereas only the outer layer of aldosteroneproducing cell clusters expresses Dab2. 30 Like CD56, Dab2 is expressed only in differentiated ZG cells: its expression is lost when ZG cells transdifferentiate into ZF cells. However, its intracellular location does not allow immunobinding separation. Dab2 is expressed in ZF-like APA cells, 30 but about a third of such APAs are negative. 31 Although the expression of Dab2 in differentiated ZG, but not in mature ZF cells, suggests it could be a marker for ZG and APA cells, the lack of Dab2 in a third of APAs questions this contention. Elucidation of Dab2 function ( Figure 1A ) could illuminate its pathophysiologic role and heterogeneous expression in APAs.
Wnt/β-Catenin Pathway
Wnt (Wingless-related integration site) are secreted proteins that control growth and stem cell renewal, acting via canonical and noncanonical Wnt pathways (see data in the onlineonly Data Supplement; Figure 1B and 1C) . The finding of immunostaining for β-catenin, the central signaling molecule of the canonical Wnt pathway, at the nuclear level in a small series of APAs with high expression of CYP11B2 suggested that Wnt/β-catenin may regulate aldosterone production. 32 Aldosterone is increased in transgenic mice with constitutive activation of β-catenin in the adrenal cortex. 33 Silencing of β-catenin in H295R cells decreased basal aldosterone production and blunted the aldosterone response to angiotensin II. 32 Activating catenin β 1 gene (CTNNB1) mutations causing Wnt/β-catenin pathway activation is associated with the adrenal malignancy 34 and 2 series of APA. 35, 36 β-Catenin enhanced aldosterone production in these APAs at several points: it increased expression of the angiotensin II type 1 (AT1) receptor, conversion of progesterone into deoxycorticosterone (the substrate for CYP11B2), and expression of the nuclear receptors NURR1 and NURR7. 32 Wnt/β-catenin pathway activation was associated with downregulation of SFRP2 (secreted frizzled-related protein 2) in APAs. 32 The SFRP2 knockout mouse shows increased plasma aldosterone levels, ectopic Dab2 plus β-catenin positive cells in the cortex and the central region. 32 Collectively, these data indicate that the Wnt inhibitor SFRP2 causes dysregulation of the Wnt/β-catenin pathway and suggest that SFRP2 and Wnt/β-catenin could be markers of APA. In the canonical pathway, the complex Wnt/Fzd binds the coreceptor LRP5/6 and, after recruiting the dishevelled protein Dsh, induces disassembling of the β-catenin complex formed by axin, Gsk3, APC, and Ck1. This causes translocation of β-catenin to the nucleus, where it binds to the TCF/LEF1 (transcription factor/lymphoid enhancer binding factor 1) proteins and triggers transcription of genes involved in growth and cell fate. In the APA, this pathway favors CYP11B2 expression, directly via the nuclear receptors NURR1 and NURR7, or indirectly by enhancing the expression of AT1 receptors and the conversion of progesterone into 11β deoxycorticosterone via CYP21. In the noncanonical, Wnt, after binding to Fzd and recruiting Dsh, activates Rho-associated kinase pathway and PKC (protein kinase C), thereby regulating cytoskeleton and Ca 2+ release from intracellular stores. Involvement of the noncanonical Wnt was suggested, but not demonstrated, in APA. D, The SHH glycoprotein binds the 12-transmembrane PTCH1 (protein patched 1) that, in turn, inhibits the SMO (smoothened receptor) leading to activation of GLI, and downstream of genes involved in cell growth and differentiation. SHH is barely detectable in the normal ZG, but markedly, albeit heterogeneously, expressed in APAs. E, Ang II, after binding to angiotensin II type 1 receptor (AT1R) receptor, activates a variety of intracellular signaling pathways, including PLC (phospholipase C) via Gq/11 (G protein subunit q/11), PKC, CaMK (calcium/ calmodulin-dependent kinases), MEK (mitogen-activated protein kinase), and ERK1/2 (extracellular signal-regulated kinase 1 and 2), JAK (Janus kinase)/signal transduction, and STAT (activators of transcription) which lead to phosphorylation of transcription factors (TF) and transcription of genes involved in steroidogenesis and cell growth.
The finding, however, of constitutive Wnt/β-catenin signaling in the entire peritumoral adrenal cortex, 11 in micro-and macronodular hyperplasia, and in nonaldosterone-producing adrenocortical tumors challenges this contention. 32, 35 Thus, whether SFRP2 and Wnt/β-catenin can isolate aldosteroneproducing cells and identify APA is doubtful.
Sonic Hedgehog Signaling
The sonic hedgehog (SHH) gene (NM_000193) codes for a glycoprotein involved in cell growth and differentiation (see data in the online-only Data Supplement; Figure 1D) . 37 ,38 SHH components are expressed in the entire adrenal cortex in children and only in the outer subcapsular ZG in adults, 11, 39, 40 suggesting that SHH may be a marker of stem/precursor cells in the adrenal cortex. SHH is barely detectable in the outer normal ZG, but is expressed in APAs with homogeneous or heterogeneous patterns 11 . SHH is also expressed in peritumoral tissue and in the hyperplasic ZG with a pattern of expression similar to CYP11B2 and Dab2. 11 This abnormal expression was associated with activation of a cluster of genes (HMGA1, TUBB3, GATA2, ZNF9, UNG, CCND2, and STAT1) involved in SHH pathways. 11 As APA and adjacent ZG present some features of stem/precursor cells, the reexpression of these fetal genes possibly represents excessive ZG cell proliferation and APA formation.
11 SHH is, however, unlikely to be a good marker of aldosterone-producing and APA cells, given its expression in both APAs and peritumoral tissue.
AT1 Receptor
Receptors for angiotensin II, a well-established stimulus of aldosterone secretion ( Figure 1E ) and cell growth, 41, 42 were reported in the adrenal cortex of several species 2 decades ago. 43, 44 Only recently, however, a systematic investigation of human adrenal specimens has shown that AT1 receptors are by far the most predominantly receptor in both normal adrenal cortex and APA; AT2 are 10-fold less expressed in the normal adrenal cortex and even less in APAs. 45 AT1 is also found in ZF and the tissue adjacent to APAs, indicating that AT1 is not exclusively involved in regulation of aldosterone. These observations together with the low expression of AT2 and the receptor for alamandine, a derivative of angiotensin (1-7), in both normal ZG and APA invalidate these receptors as markers.
DACH1: A CYP11B2 Suppressor
The nuclear protein DACH1 (Dachshund family transcription 1, NM_004392.6) acts as a tumor suppressor by binding to Smad4. 46, 47 DACH1 was found to be 10-fold more expressed in ZG than in ZF and APA cells 48 ; its silencing in H295R cells increases aldosterone synthesis and overexpression decreases it. Stimulation of primary human adrenal cells with angiotensin II to markedly increase CYP11B2, leading to 2.4-fold increase in aldosterone production, blunted DACH1 gene expression. 48 Hence, DACH1 regulates ZG cell function 48 through mechanisms yet unknown. Because overexpression of DACH1 increased SMAD4 expression and enhanced the TGF-β1 (transforming growth factor-β1) signaling pathway, it was suggested that activation of DACH1/TGF-β1 pathway switches off aldosterone production and that such an inhibitory pathway is blunted in APA (Figure 2 ). 48 Overexpression of TGFβ1 in mice decreases aldosterone production, and decreased expression of TGFβ1 increases aldosterone Figure 2 . Regulation of aldosterone secretion by DACH1 (Dachshund family transcription 1) in normal zona glomerulosa (ZG) and aldosteroneproducing adenoma (APA) cells. DACH1 was found 10-fold more expressed in ZG than in zona fasciculata (ZF) and APA (A). Angiotensin II blunts expression of DACH1 and thus increases CYP11B2 transcription and aldosterone production (B); contrarily, overexpression of DACH1, by increasing SMAD4 expression and activating the TGF-β1 (transforming growth factor-β1) signaling, turns off aldosterone production in the normal ZG. Blunted expression of DACH1 (likely independently from angiotensin II) could activate aldosterone production in APA (C).
production. 49 Whether DACH1 can be a negative marker of ZG and APA cells remains to be proven.
LGR5 Suppresses CYP11B2 in APA
LGR5 (leucine rich repeat containing G protein coupled receptor 5; NM_001277227.1) is a 907-amino acid protein involved in growth and proliferation (see data in the online-only Data Supplement). A transcriptome analysis of laser capture microdissected ZG and ZF cells from adrenal cortex adjacent to APA or pheochromocytoma showed that expression of LGR5 was 25-fold greater in ZG than in ZF and was the top hit among 213 overexpressed genes in ZG compared with ZF. 50 A radial streaking of LGR5 into ZF was observed in some serial sections, presumably reflecting the centripetal migration of ZG cells during development. 50 Expression of the gene coding for the LGR5 cognate ligand R-spondin-3 was also upregulated 5-fold in ZG compared with ZF. In addition, 18 of the 213 genes more expressed in the ZG than ZF-encoded proteins associated with the Wnt signaling pathway (see later); translation of some of these mRNA into effector proteins was confirmed with immunohistochemistry. 50 LGR5 showed specific ZG expression and colocalization with β-catenin, LEF1, the nuclear transcription factor activated by β-catenin, c-Jun, the target of the polarity noncanonical Wnt pathways, and phospho-c-Jun. 50 Its silencing in H295R cells and normal primary adrenal cells increases both CYP11B2 expression and aldosterone production; it also increases activity of the Wnt transcription factors TCF/LEF (transcription factor/ lymphoid enhancer binding factor) and AP1/Jun, indicating that LGR5 blunts aldosterone synthesis via Wnt pathways (Figure 3) . Conversely, overexpression of LGR5 agonist cognate R-spondin-3 has opposite effects. 50 The lower expression of LGR5 observed in APA cells than in the adjacent ZG also supports the contention that LGR5 blunts aldosterone synthesis, by suppressing Wnt pathway, whose activation results in aldosterone synthesis (see later). 32, 33, 50 Whether LGR5 can be used as a tool to isolate APA from surrounding non-APA cells remains to be investigated. Whether the LGR5 pathway is a feasible therapeutic target for mitigating hyperaldosteronism is an intriguing possibility.
Pre-B Lymphocyte Protein 3
VPREB3 (pre-B lymphocyte protein 3) is expressed in APAs and adjacent tissues, but not in cortisol-producing adenomas (see data in the online-only Data Supplement). 51 In the normal cortex, it occurs mainly in the normal ZG, with only few positive cells in ZF. 52 The colocalization of VPREB3 with CYP11B2 and the increased expression VPREB3 in H295R cells after angiotensin II stimulation suggest that VPREB3 could be a marker of aldosterone-producing cells. 52 Nevertheless, the expression of VPREB3 in some ZF cells and the correlation between expression of VPREB3 and HSD3B2, but not HSD3B1, does not support VPREB3 as marker of ZG and APA cells.
Visinin Like 1
VSNL1 (visinin like 1; NM_003385.4) is a protein modulating intracellular Ca 2+ signaling pathways (see data in the online-only Data Supplement). Overexpression of VSNL1 upregulates basal and angiotensin II-stimulated CYP11B2 expression in the H295R cells.
53 VSNL1 was reported to be highly expressed in the rat adrenal ZG, to be upregulated in APAs, 53 and to be acutely downregulated by the adrenocorticotropic hormone. 54 APAs harboring KCNJ5 mutations overexpress VSNL1 compared with wild-type APAs, resulting in inhibition of Ca 2+ -induced apoptosis. The role(s) of VSNL1 in adrenal ZG physiology, and whether it is a marker of aldosterone-producing and APA cells, remains to be fully explored.
Nephronectin
NPNT (nephronectin; NM_001184690.1) is an extracellular matrix protein that has been recently described in the normal LGR5, by acting as a receptor for RSPO (R-spondins), amplifies the effect of Wnt/β-catenin signaling. After binding of the complex Wnt/Fzd to LRP5 and recruitment of Dsh, the β-catenin complex disassembles, thus allowing translocation of β-catenin to the nucleus, where it regulates gene transcription (see Figure 1 for details on Wnt/β-catenin signaling). It was posited that high levels of LGR5 in the ZG prevent abnormal aldosterone synthesis, whereas lower levels in APA would play a permissive role.
adrenal cortex, with higher expression in ZG than in ZF cells (see data in the online-only Data Supplement). 55 The expression in ZG-like APAs, but not in the adjacent tissue, suggests that NPNT could play a role in APA, a contention supported by the increased, or reduced, CYP11B2 expression levels after overexpressing or silencing NPNT gene, respectively, in H295R cells. Modulation of Wnt caused parallel changes of NPNT, and vice versa, suggesting a bidirectional regulation between Wnt and NPNT. NPNT silencing caused apoptosis through reduction of BCL2, a prosurvival factor, suggesting a role of NPNT in the adrenal growth. Why NPNT is overexpressed only in ZG-like, but not ZF-like APAs, is totally unknown.
Neurofilament Medium Polypeptide
The neurofilament medium polypeptide (NEFM) gene (NM_005382), which encodes the medium neurofilament protein, was recently found in normal ZG and ZG-like APAs but apparently not in normal ZF or in ZF-like APAs (see data in the online-only Data Supplement). 56 Silencing of NEFM in H295R cells increased aldosterone production and decreased CYP11B2 and NR4A2 mRNA expression levels and also enhanced cell proliferation, suggesting that NEFM suppresses aldosterone synthesis and growth. 56 NEFM interacts with dopamine receptor D1, which stimulates aldosterone secretion in both ZG and ZG-like APAs cells. 56 NEFM, by binding D1 receptor and internalizing it, promotes its desensitization and therefore blunts aldosterone secretion. 56 Because of the specific expression in ZG-like APAs, NEFM could be useful for identification of ZG-like APAs.
3β-Hydroxysteroid Dehydrogenase/ Isomerase
The 2 isoforms HSD3B1 and HSD3B2 (3β-hydroxysteroid dehydrogenase/isomerase) share 93.5% identity at the amino acid sequence (see data in the online-only Data Supplement). 57 Immunohistochemistry with specific monoclonal antibodies showed that HSD3B1 is expressed in ZG but not in ZF, whereas HSD3B2 is equally expressed in ZG and ZF and also in APA. In APA, HSD3B1 is expressed at low levels but correlates with the expression of CYP11B2. 58 Hence, the isoform HSD3B1 could be a promising marker for APA, a hypothesis that deserves further specific investigation.
Nuclear Factor Erythroid-Derived 2 and Reduced Nicotinamide Adenine Dinucleotide Phosphate
Analysis of genes differentially regulated in ZG versus ZF showed overexpression in ZG versus ZF, and also in APA versus ZG, of nuclear factor erythroid-derived 2 (NM_006164.4), a transcription factor that regulates expression of antioxidative proteins. 59 An involvement of this pathway is consistent with the increased levels of NOx2 and p22phox, which forms the catalytic core of nicotinamide adenine dinucleotide phosphate, in patients with APA. 60, 61 While probably relevant for the pathophysiology of APA, the lack of data currently precludes use of either nuclear factor erythroid-derived 2 or nicotinamide adenine dinucleotide phosphate as markers of aldosterone-producing cells.
Conclusions and Perspectives
For decades, expression of CYP11B2 was thought to be the signature of ZG and APA cells, but this notion turned out to be fallacious. Hence, the search for specific markers of ZG and APA cells was initiated. By using advanced techniques, different laboratories have made a tremendous effort to identify genes and proteins over-or underexpressed in ZG and APA cells that could be involved in steroidogenesis or cell growth. The results obtained thus far, although promising, raised several questions that still await answers. However, waiting for the marker of aldosterone-producing cells, a set of markers that can be reasonably used to diagnose an APA include CD56 and Dab2. This is because both are markedly expressed in ZG and APA, with the former also expressed in a percentage of ZF cells and the latter missing in some ZG cells. Combination of the 2 markers would allow identification of all aldosteroneproducing cells. Moreover, because CD56 is expressed at the cell membrane level, it can be successfully used to isolate aldosterone-producing cells for research purposes.
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